Dariohealth Corp - DRIO STOCK NEWS

DarioHealth Corp. (Nasdaq: DRIO) has appointed Eitan Shay as Chief Product Officer and Arnaud Robert as Strategic Advisor to the CEO. These strategic appointments aim to enhance Dario's digital therapeutics platform amidst increasing market demand. Eitan Shay brings extensive experience from Livongo, Teladoc Health, and Meta Platforms. On April 3, 2023, Shay was granted stock options to purchase 100,000 shares at $3.93, alongside performance-based options for an additional 80,000 shares. Dario's innovative solutions empower individuals to manage chronic conditions more effectively, reinforcing the company's commitment to continuous improvement in healthcare delivery.

DarioHealth Corp. (Nasdaq: DRIO) has announced a significant contract with a leading nationwide Pharmacy Benefits Manager (PBM) to provide its digital therapeutics, including a diabetes solution, starting in Q2 2023. This contract marks the first outcome of Dario's strategic partnership with Sanofi and is expected to replace the PBM's existing diabetes solution. The initiative aims to enhance Dario's portfolio in the employer and payer markets, generating revenue growth through 2023. The partnership is a vital step in Dario's strategy to expand its digital health solutions, demonstrating the value of collaborations in the rapidly growing digital therapeutics sector.

DarioHealth Corp. (Nasdaq: DRIO) has entered into a strategic partnership with Amwell (NYSE: AMWL), integrating Dario's cardiometabolic solutions into Amwell's digital care delivery platform, which covers over 90 million lives. This collaboration aims to enhance the care experience for individuals with conditions such as diabetes and hypertension by providing access to Dario's personalized digital health solutions. The Dario cardiometabolic suite will be available to Amwell customers in the second half of 2023, promoting a seamless member journey and supporting better health management.

Amwell (NYSE: AMWL) has announced the launch of its new cardiometabolic program, enhancing its ecosystem of digital health solutions to better serve members with chronic diseases like diabetes and high blood pressure. This initiative, in partnership with DarioHealth (Nasdaq: DRIO), integrates Dario's personalized digital therapeutic solutions into the Amwell platform, facilitating seamless referrals for clinicians. The program aims to improve health outcomes by ensuring continuous care and engagement for over one-third of Americans living with metabolic conditions. Through connected devices and coaching, members experience a holistic approach to managing their health.

DarioHealth Corp. (Nasdaq: DRIO) announced new research in Pain Reports showing that personalized digital therapeutics can effectively reduce back pain. The study analyzed data from 3,610 users over three weeks, revealing significant pain reduction linked to a posture training program enhanced by machine learning. This personalized approach is crucial for optimizing user experiences and promoting ongoing engagement with digital health solutions. Dario aims to empower users through customized interventions, transforming chronic condition management.

DarioHealth Corp. (Nasdaq: DRIO) reported a significant financial turnaround for 2022, with total revenue reaching $27.7 million, marking a 34.8% increase from 2021. The pivot towards a B2B model drove commercial revenue, contributing 59% to total revenue. The operating loss in Q4 2022 dropped to $9 million, a 58% decrease compared to Q4 2021. Cash reserves stood at $49.3 million. Dario achieved over 100 B2B contracts, with total signed value surpassing $65 million. The company anticipates ongoing financial improvement, targeting gross margins of approximately 70% as its multi-condition platform gains traction.

DarioHealth Corp. (NASDAQ: DRIO) will announce its fourth quarter and full year 2022 financial results on March 9, 2023, before the market opens. A conference call and webcast will follow at 8:30 am ET. The call will feature CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David. Participants can join by dialing 1-877-451-6152 for domestic calls or 1-201-389-0879 for international. A replay will be available post-call, with further details accessible via the provided webcast link. DarioHealth specializes in digital therapeutics, focusing on personalized health solutions for chronic conditions.

DarioHealth Corp. (Nasdaq: DRIO) presented two clinical studies at the ATTD 2023 conference, highlighting its digital-first chronic care solution's effectiveness. One study focused on Type 2 diabetes, demonstrating an 18% reduction in blood glucose levels among users engaged with a coach compared to 11% for those without coaching. The second study revealed that older adults experienced a 31% reduction in level 1 hypoglycemic events and a 53% reduction in level 2 events after 6 months of using Dario's platform. These results emphasize the potential of combining human coaching with digital interventions for improved health outcomes.

DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the Cowen 43rd Annual Healthcare Conference, scheduled for March 6-8, 2023, at the Boston Marriott Copley Place. CEO Erez Raphael and President Rick Anderson will engage in a fireside chat on March 6 from 10:30 to 11:00 AM ET. A live webcast will be available at this link and on DarioHealth's Investor Relations website, with a replay accessible for 90 days post-event. DarioHealth specializes in digital therapeutics, addressing chronic conditions through a comprehensive AI-powered platform.